Candidiasis News and Research

RSS

Candiadiasis, or Thrush, is a fungal infection caused by a group of yeast. There is a score of Candida species, the commonest of which is Candida albicans. They normally inhabit the surfaces and mucus linings of the human body. This includes mouth, vaginal cavity gastrointestinal tract etc.

Male circumcision may protect against HPV infection in males and females

Study highlights the protective effect of male circumcision on the prevalence, incidence, and clearance of HPV.

10 Apr 2023

Antifungal tolerance in Candida auris contributes to treatment failure

A recent study published in the journal Biomedicines aimed to determine the antifungal tolerance of Candida auris (C. auris) to all three classes of antifungal drugs commonly used to treat invasive candidiasis.

23 Mar 2023

Candida auris infection without epidemiologic links to a prior outbreak

The Centers for Disease Control and Prevention (CDC) has classified Candida auris (C. auris) as an urgent public threat due to its role in elevating mortality, its ability to persist in hospital environments, and the high possibility of developing pan-drug resistance.

23 Mar 2023

Does recurrent bacterial vaginosis impact quality of life?

A recent BMC Women's Health study performed a survey to understand how bacterial vaginosis affects women’s quality of life and what treatment they underwent.

22 Mar 2023

The role of the fungal mycobiome in women's health

Researchers discuss the association between human mycobiota and female health.

15 Mar 2023

Study summarizes two cases of Cronobacter illness in infants linked to powdered infant formula and breast pump equipment

The findings indicate that C. sakazakii bacteria are common in the environment, and protocols for safe and hygienic food preparation for infants are essential.

6 Mar 2023

Novel antifungal medications urgently needed to control COVID-19-associated fungal infections

Every day we inhale thousands of potentially pathogenic fungal spores, but our immune system simply eliminates them.

9 Sep 2022

Discovery may lead to the development of new systems of antifungal drugs

Mycosis is an infectious disease caused by parasitic mold or yeast and treated with an antifungal, a subgroup of antibiotics.

26 Aug 2022

High prevalence of fungal secondary infections among COVID-19 patients

Researchers analyze literature to explore the frequency of secondary fungal infections among COVID-19 patients.

2 Aug 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

Human gingival epithelial cells become damaged by cannabis smoke condensate

In a new study, scientists evaluated the effect of cannabis smoke condensate (CSC) on the gingival epithelial cells.

5 Jul 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022

Antibiotics disrupt the immune system in the gut leading to fungal infection

Patients prescribed antibiotics in hospital are more likely to get fungal infections because of disruption to the immune system in the gut, according to a new study from the University of Birmingham and National Institutes of Health.

13 May 2022

Pain neuron-derived peptide protects mice from endotoxic death by enhancing brain ATP production

Sepsis is a high-mortality disease that arises when the body's immune reaction to pathogens causes multi-organ defects.

9 Mar 2022

Researchers identify genes that cause resistance to treatment of Candida glabrata fungus

It is estimated that 80% of women will suffer from vaginal candidiasis at least once in their lives. In addition to superficial infections, which can be oral or vaginal and do not usually have a serious prognosis, fungi of the Candida genus can cause systemic diseases in immunocompromised individuals and these are fatal in 40% of cases.

25 Oct 2021

New color-changing thread in tampons or sanitary napkins helps diagnose vulvovaginal yeast infections

The yeast Candida albicans can cause itchy, painful urinary tract and vaginal yeast infections. For women in low-resource settings who lack access to healthcare facilities, these infections create substantial social and economic burdens.

20 May 2021

Can SARS-CoV-2 still be transmissible once symptoms have subsided?

Researchers based at the University of Missouri, in partnership with U.S. government science facilities in Maryland, have reported that individuals severely infected with SARS-CoV-2 may be able to continue shedding infectious viral RNA for over three weeks after the symptomatic infection has passed.

22 Mar 2021

ERC Synergy project explores causes of drug tolerance in intractable fungal infections

Over the next six years, research groups at Charité - Universitätsmedizin Berlin and Tel Aviv University will study how invasive fungal pathogens are able to evade treatments and develop tolerance to antifungal drugs.

10 Nov 2020

Hybrid fungus involved in lung infections discovered

Aspergillus latus, a species of fungus previously found only in soil or plants, has been found for the first time in a hospital environment by an international group of researchers.

19 Jul 2020

Wasan lab develops novel oral formulation to treat systemic fungal infections

The Wasan Laboratory in the Faculty of Pharmaceutical Sciences at the University of British Columbia in partnership with iCo Therapeutics Inc. (Vancouver BC, Canada) have developed a novel oral formulation of Amphotericin B to treat systemic fungal and parasitic infections.

23 Mar 2020